ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 183 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $288,000 | +17.6% | 10,000 | +29.9% | 0.01% | +40.0% |
| Q3 2016 | $245,000 | -73.3% | 7,701 | -76.5% | 0.01% | -70.6% |
| Q1 2016 | $917,000 | -64.2% | 32,770 | -54.4% | 0.02% | -34.6% |
| Q4 2015 | $2,564,000 | +97.2% | 71,920 | +82.9% | 0.03% | +116.7% |
| Q3 2015 | $1,300,000 | +150.5% | 39,319 | +217.5% | 0.01% | +140.0% |
| Q2 2015 | $519,000 | -50.9% | 12,383 | -61.8% | 0.01% | -50.0% |
| Q1 2015 | $1,058,000 | -61.1% | 32,450 | -62.1% | 0.01% | -41.2% |
| Q4 2014 | $2,718,000 | +62.1% | 85,586 | +26.4% | 0.02% | +88.9% |
| Q3 2014 | $1,677,000 | +81.9% | 67,694 | +65.9% | 0.01% | +125.0% |
| Q2 2014 | $922,000 | -31.0% | 40,800 | -25.7% | 0.00% | -42.9% |
| Q1 2014 | $1,336,000 | -46.2% | 54,905 | -44.8% | 0.01% | -46.2% |
| Q4 2013 | $2,483,000 | -29.2% | 99,383 | -22.2% | 0.01% | -38.1% |
| Q3 2013 | $3,508,000 | +12.1% | 127,727 | -25.9% | 0.02% | +10.5% |
| Q2 2013 | $3,130,000 | – | 172,457 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 25,819,768 | $972,631,000 | 7.89% |
| SECTORAL ASSET MANAGEMENT INC | 822,392 | $30,980,000 | 3.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 240,773 | $9,068,000 | 3.53% |
| HARVEY CAPITAL MANAGEMENT INC | 230,700 | $8,690,000 | 3.51% |
| Palo Alto Investors LP | 1,641,030 | $61,818,000 | 2.60% |
| GARRISON BRADFORD & ASSOCIATES INC | 73,350 | $2,763,000 | 2.31% |
| EMORY UNIVERSITY | 52,977 | $1,996,000 | 1.58% |
| Sivik Global Healthcare LLC | 120,000 | $4,520,000 | 1.54% |
| Stanley-Laman Group, Ltd. | 143,876 | $5,420,000 | 1.45% |
| ACUTA CAPITAL PARTNERS, LLC | 170,000 | $6,404,000 | 1.15% |